<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34823547</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-2094</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of neuroinflammation</Title><ISOAbbreviation>J Neuroinflammation</ISOAbbreviation></Journal><ArticleTitle>Early upregulation of cytosolic phospholipase A<sub>2</sub>&#x3b1; in motor neurons is induced by misfolded SOD1 in a mouse model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>274</StartPage><MedlinePgn>274</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">274</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12974-021-02326-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a fatal multifactorial neurodegenerative disease characterized by the selective death of motor neurons. Cytosolic phospholipase A<sub>2</sub> alpha (cPLA<sub>2</sub>&#x3b1;) upregulation and activation in the spinal cord of ALS patients has been reported. We have previously shown that cPLA<sub>2</sub>&#x3b1; upregulation in the spinal cord of mutant SOD1 transgenic mice (SOD1<sup>G93A</sup>) was detected long before the development of the disease, and inhibition of cPLA<sub>2</sub>&#x3b1; upregulation delayed the disease's onset. The aim of the present study was to determine the mechanism for cPLA<sub>2</sub>&#x3b1; upregulation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Immunofluorescence analysis and western blot analysis of misfolded SOD1, cPLA<sub>2</sub>&#x3b1; and inflammatory markers were performed in the spinal cord sections of SOD1<sup>G93A</sup> transgenic mice and in primary motor neurons. Over expression of mutant SOD1 was performed by induction or transfection in primary motor neurons and in differentiated NSC34 motor neuron like cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Misfolded SOD1 was detected in the spinal cord of 3&#xa0;weeks old mutant SOD1<sup>G93A</sup> mice before cPLA<sub>2</sub>&#x3b1; upregulation. Elevated expression of both misfolded SOD1 and cPLA<sub>2</sub>&#x3b1; was specifically detected in the motor neurons at 6&#xa0;weeks with a high correlation between them. Elevated TNF&#x3b1; levels were detected in the spinal cord lysates of 6&#xa0;weeks old mutant SOD1<sup>G93A</sup> mice. Elevated TNF&#x3b1; was specifically detected in the motor neurons and its expression was highly correlated with cPLA<sub>2</sub>&#x3b1; expression at 6&#xa0;weeks. Induction of mutant SOD1 in primary motor neurons induced cPLA<sub>2</sub>&#x3b1; and TNF&#x3b1; upregulation. Over expression of mutant SOD1 in NSC34 cells caused cPLA<sub>2</sub>&#x3b1; upregulation which was prevented by antibodies against TNF&#x3b1;. The addition of TNF&#x3b1; to NSC34 cells caused cPLA<sub>2</sub>&#x3b1; upregulation in a dose dependent manner.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Motor neurons expressing elevated cPLA<sub>2</sub>&#x3b1; and TNF&#x3b1; are in an inflammatory state as early as at 6&#xa0;weeks old mutant SOD1<sup>G93A</sup> mice long before the development of the disease. Accumulated misfolded SOD1 in the motor neurons induced cPLA<sub>2</sub>&#x3b1; upregulation via induction of TNF&#x3b1;.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malada Edelstein</LastName><ForeName>Yafa Fetfet</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Immunology and Infectious Diseases Laboratory, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev and Soroka University Medical Center, 84105, Beer Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomonov</LastName><ForeName>Yulia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Immunology and Infectious Diseases Laboratory, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev and Soroka University Medical Center, 84105, Beer Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadad</LastName><ForeName>Nurit</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Immunology and Infectious Diseases Laboratory, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev and Soroka University Medical Center, 84105, Beer Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfahel</LastName><ForeName>Leenor</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology, Faculty of Health Sciences and The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Israelson</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology, Faculty of Health Sciences and The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4169-485X</Identifier><AffiliationInfo><Affiliation>Immunology and Infectious Diseases Laboratory, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev and Soroka University Medical Center, 84105, Beer Sheva, Israel. ral@bgu.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Miss Dorothy Polayes</GrantID><Agency>Donation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuroinflammation</MedlineTA><NlmUniqueID>101222974</NlmUniqueID><ISSNLinking>1742-2094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.4</RegistryNumber><NameOfSubstance UI="D054513">Group IV Phospholipases A2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054513" MajorTopicYN="N">Group IV Phospholipases A2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="Y">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Cytosolic phospholipase A2&#x3b1;</Keyword><Keyword MajorTopicYN="N">Misfolded SOD1</Keyword><Keyword MajorTopicYN="N">Motor neurons</Keyword><Keyword MajorTopicYN="N">Mutant SOD1G93A</Keyword><Keyword MajorTopicYN="N">TNF&#x3b1;</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34823547</ArticleId><ArticleId IdType="pmc">PMC8620709</ArticleId><ArticleId IdType="doi">10.1186/s12974-021-02326-5</ArticleId><ArticleId IdType="pii">10.1186/s12974-021-02326-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ince P, Highley J, Kirby J, Wharton S, Takahashi H, Strong M, Shaw P. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol. 2011;122:657&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">22105541</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P. Genetics of sporadic ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:S37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11465923</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara T, Ishigaki S, Yamamoto M, Liang Y, Niwa J, Takeuchi H, Doyu M, Sobue G. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem. 2002;80:158&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu I, Phatnani H, Kuligowski M, Tapia J, Carrasco M, Zhang M, Maniatis T, Carroll M. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc Natl Acad Sci U S A. 2009;106:20960&#x2013;20965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791631</ArticleId><ArticleId IdType="pubmed">19933335</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D, Henkel J, Xiao Q, Zhao W, Wang J, Yen A, Siklos L, McKercher S, Appel S. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2006;103:16021&#x2013;16026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re D, Nagata T, Chalazonitis A, Jessell T, Wichterle H, Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer RM, Roberts EF, Manetta J, Putnam JE. The Ca2(+)-sensitive cytosolic phospholipase A2 is a 100-kDa protein in human monoblast U937 cells. J Biol Chem. 1991;266:5268&#x2013;5272.</Citation><ArticleIdList><ArticleId IdType="pubmed">2002059</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark JD, Milona N, Knopf JL. Purification of a 110-kilodalton cytosolic phospholipase A2 from the human monocytic cell line U937. Proc Natl Acad Sci USA. 1990;87:7708&#x2013;7712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54817</ArticleId><ArticleId IdType="pubmed">2217203</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson DT, Lemere CA, Selkoe DJ, Clemens JA. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer&#x2019;s disease brain. Neurobiol Dis. 1996;3:51&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9173912</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens JA, et al. Reactive glia express cytosolic phospholipase A2 after transient global forebrain ischemia in the rat. Stroke. 1996;27:527&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">8610324</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson D, Rash K, Smalstig B, Roberts E, Johnstone E, Sharp J, Panetta J, Little S, Kramer R, Clemens J. Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration. Glia. 1999;27:110&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">10417811</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, Kakita A, Takahashi H, Ihara Y, Nobukuni K, Fujimura H, Sakoda S, Kobayashi M. Increased expression and activation of cytosolic phospholipase A2 in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 2010;119:345&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">20066429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M, Kipiani K, Petri S, Choi D, Chen J, Calingasan N, Beal M. Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2005;93:403&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">15816863</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomonov Y, Hadad N, Levy R. Reduction of cytosolic phospholipase A2alpha upregulation delays the onset of symptoms in SOD1G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2016;13:134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888471</ArticleId><ArticleId IdType="pubmed">27250836</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston JA, Dalton MJ, Gurney ME, Kopito RR. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2000;97:12571&#x2013;12576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18805</ArticleId><ArticleId IdType="pubmed">11050163</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron R, Babcock AA, Nemirovsky A, Finsen B, Monsonego A. Accelerated microglial pathology is associated with Abeta plaques in mouse models of Alzheimer&#x2019;s disease. Aging Cell. 2014;13:584&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326940</ArticleId><ArticleId IdType="pubmed">24641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Shmelzer Z, Haddad N, Admon E, Pessach I, Leto TL, Eitan-Hazan Z, Hershfinkel M, Levy R. Unique targeting of cytosolic phospholipase A2 to plasma membranes mediated by the NADPH oxidase in phagocytes. J Cell Biol. 2003;162:683&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173789</ArticleId><ArticleId IdType="pubmed">12913107</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyton-Jaimes MF, Benaim C, Abu-Hamad S, Kahn J, Guetta A, Bucala R, Israelson A. Endogenous macrophage migration inhibitory factor reduces the accumulation and toxicity of misfolded SOD1 in a mouse model of ALS. Proc Natl Acad Sci USA. 2016;113:10198&#x2013;10203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018779</ArticleId><ArticleId IdType="pubmed">27551074</ArticleId></ArticleIdList></Reference><Reference><Citation>Royo NC, Vandenberghe LH, Ma JY, Hauspurg A, Yu L, Maronski M, Johnston J, Dichter MA, Wilson JM, Watson DJ. Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity. Brain Res. 2008;1190:15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2367141</ArticleId><ArticleId IdType="pubmed">18054899</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier O, Bohm J, Dahm M, Bruck S, Beyer C, Johann S. Differentiated NSC-34 motoneuron-like cells as experimental model for cholinergic neurodegeneration. Neurochem Int. 2013;62:1029&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">23562846</ArticleId></ArticleIdList></Reference><Reference><Citation>Shvil N, Banerjee V, Zoltsman G, Shani T, Kahn J, Abu-Hamad S, Papo N, Engel S, Bernhagen J, Israelson A. MIF inhibits the formation and toxicity of misfolded SOD1 amyloid aggregates: implications for familial ALS. Cell Death Dis. 2018;9:107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833700</ArticleId><ArticleId IdType="pubmed">29371591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadad N, Tuval L, Elgazar-Carmom V, Levy R, Levy R. Endothelial ICAM-1 protein induction is regulated by cytosolic phospholipase A2alpha via both NF-kappaB and CREB transcription factors. J Immunol. 2011;186:1816&#x2013;1827.</Citation><ArticleIdList><ArticleId IdType="pubmed">21199900</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CM, Lee IT, Chi PL, Cheng SE, Hsiao LD, Hsu CK. TNF-alpha induces cytosolic phospholipase A2 expression via Jak2/PDGFR-dependent Elk-1/p300 activation in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2014;306:L543&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">24441870</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu NK, Deng LX, Zhang YP, Lu QB, Wang XF, Hu JG, Oakes E, Bonventre JV, Shields CB, Xu XM. Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury. Ann Neurol. 2014;75:644&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320750</ArticleId><ArticleId IdType="pubmed">24623140</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu NK, Xu XM. Phospholipase A2 and its molecular mechanism after spinal cord injury. Mol Neurobiol. 2010;41:197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">20127525</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu NK, Zhang YP, Han S, Pei J, Xu LY, Lu PH, Shields CB, Xu XM. Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury. J Neuropathol Exp Neurol. 2007;66:932&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">17917587</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu NK, Zhang YP, Titsworth WL, Jiang X, Han S, Lu PH, Shields CB, Xu XM. A novel role of phospholipase A2 in mediating spinal cord secondary injury. Ann Neurol. 2006;59:606&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">16498630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas KK, Svensson CI, Hua XY, Yaksh TL, Dennis EA. Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2. Br J Pharmacol. 2005;144:940&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1576074</ArticleId><ArticleId IdType="pubmed">15685208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonventre JV. Roles of phospholipases A2 in brain cell and tissue injury associated with ischemia and excitotoxicity. J Lipid Mediat Cell Signal. 1997;16:199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9246608</ArticleId></ArticleIdList></Reference><Reference><Citation>Farooqui AA, Yang HC, Rosenberger TA, Horrocks LA. Phospholipase A2 and its role in brain tissue. J Neurochem. 1997;69:889&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">9282910</ArticleId></ArticleIdList></Reference><Reference><Citation>Titsworth WL, Liu NK, Xu XM. Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury. CNS Neurol Disord Drug Targets. 2008;7:254&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2800081</ArticleId><ArticleId IdType="pubmed">18673210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M, Vallarola A, Lidonnici D, Battaglia E, Gensano F, Spaltro G, Fiordaliso F, Corbelli A, Garetto S, Martini E, et al. Lack of TNF-alpha receptor type 2 protects motor neurons in a cellular model of amyotrophic lateral sclerosis and in mutant SOD1 mice but does not affect disease progression. J Neurochem. 2015;135:109&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">25940956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazuki Ohuchi K, Tsuruma K, Masamitsu Shimazawa M, Junji Nakamura J, Hideaki HH. The novel cPLA2 inhibitor AK106-001616 has a protective effect on SOD1G93A-induced cell death in NSC34 murine motor neuron-like cell. Pharmacol Pharmacy. 2016;7:193&#x2013;199.</Citation></Reference><Reference><Citation>Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, Jacobsson J, Rosquist R, Marklund SL, Brannstrom T. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS ONE. 2010;5:e11552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904380</ArticleId><ArticleId IdType="pubmed">20644736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, Yamada T, Kikuchi H, Taniwaki T, Murai H, et al. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer&#x2019;s disease. FASEB J. 2005;19:255&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548589</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley SV, Holland EC, Liu GY, Thomas D, Hyun TS, Ross TS. Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res. 2007;67:3609&#x2013;3615.</Citation><ArticleIdList><ArticleId IdType="pubmed">17440072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ames HM, Bichakjian CK, Liu GY, Oravecz-Wilson KI, Fullen DR, Verhaegen ME, Johnson TM, Dlugosz AA, Ross TS. Huntingtin-interacting protein 1: a Merkel cell carcinoma marker that interacts with c-Kit. J Invest Dermatol. 2011;131:2113&#x2013;2120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174286</ArticleId><ArticleId IdType="pubmed">21697888</ArticleId></ArticleIdList></Reference><Reference><Citation>Israelson A, Arbel N, Da Cruz S, Ilieva H, Yamanaka K, Shoshan-Barmatz V, Cleveland DW. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron. 2010;67:575&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941987</ArticleId><ArticleId IdType="pubmed">20797535</ArticleId></ArticleIdList></Reference><Reference><Citation>Shteinfer-Kuzmine A, Argueti S, Gupta R, Shvil N, Abu-Hamad S, Gropper Y, Hoeber J, Magri A, Messina A, Kozlova EN, et al. A VDAC1-derived N-terminal peptide inhibits mutant SOD1-VDAC1 interactions and toxicity in the SOD1 model of ALS. Front Cell Neurosci. 2019;13:346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6702328</ArticleId><ArticleId IdType="pubmed">31474832</ArticleId></ArticleIdList></Reference><Reference><Citation>Israelson A, Ditsworth D, Sun S, Song S, Liang J, Hruska-Plochan M, McAlonis-Downes M, Abu-Hamad S, Zoltsman G, Shani T, et al. Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1. Neuron. 2015;86:218&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393372</ArticleId><ArticleId IdType="pubmed">25801706</ArticleId></ArticleIdList></Reference><Reference><Citation>Maatkamp A, Vlug A, Haasdijk E, Troost D, French PJ, Jaarsma D. Decrease of Hsp25 protein expression precedes degeneration of motoneurons in ALS-SOD1 mice. Eur J Neurosci. 2004;20:14&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">15245475</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato S, Saeki Y, Aoki M, Nagai M, Ishigaki A, Itoyama Y, Kato M, Asayama K, Awaya A, Hirano A, Ohama E. Histological evidence of redox system breakdown caused by superoxide dismutase 1 (SOD1) aggregation is common to SOD1-mutated motor neurons in humans and animal models. Acta Neuropathol. 2004;107:149&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">14648077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Belford ME, Lennon N, Bacskai BJ, Hyman BT, Trotti D, Brown RH., Jr Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron. 2004;43:19&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233914</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolossov VL, Sivaguru M, Huff J, Luby K, Kanakaraju K, Gaskins HR. Airyscan super-resolution microscopy of mitochondrial morphology and dynamics in living tumor cells. Microsc Res Tech. 2018;81:115&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">29131445</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieben C, Douglass KM, Guichard P, Manley S. Super-resolution microscopy to decipher multi-molecular assemblies. Curr Opin Struct Biol. 2018;49:169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">29621666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazan-Halevy I, Seger R, Levy R. The requirement of both extracellular regulated kinase and p38 mitogen-activated protein kinase for stimulation of cytosolic phospholipase A(2) activity by either FcgammaRIIA or FcgammaRIIIB in human neutrophils. A possible role for Pyk2 but not for the Grb2-Sos-Shc complex. J Biol Chem. 2000;275:12416&#x2013;12423.</Citation><ArticleIdList><ArticleId IdType="pubmed">10777525</ArticleId></ArticleIdList></Reference><Reference><Citation>Szaingurten-Solodkin I, Hadad N, Levy R. Regulatory role of cytosolic phospholipase A2alpha in NADPH oxidase activity and in inducible nitric oxide synthase induction by aggregated Abeta1-42 in microglia. Glia. 2009;57:1727&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pubmed">19455582</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagy-Bross C, Hadad N, Levy R. Cytosolic phospholipase Alpha upregulation mediates apoptotic neuronal death induced by aggregated amyloid-beta peptide. Neurochem Int. 2013;63:541&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">24044897</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagy-Bross C, Kasianov K, Solomonov Y, Braiman A, Friedman A, Hadad N, Levy R. The role of cytosolic phospholipase A alpha in amyloid precursor protein induction by amyloid beta: implication for neurodegeneration. J Neurochem. 2014;132:559&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">25533654</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Lin CC, Lee IT, Lee HC, Yang CM. Activation and induction of cytosolic phospholipase A2 by TNF-alpha mediated through Nox2, MAPKs, NF-kappaB, and p300 in human tracheal smooth muscle cells. J Cell Physiol. 2011;226:2103&#x2013;2114.</Citation><ArticleIdList><ArticleId IdType="pubmed">21520062</ArticleId></ArticleIdList></Reference><Reference><Citation>Malada-Edelstein YF, Hadad N, Levy R. Regulatory role of cytosolic phospholipase A2 alpha in the induction of CD40 in microglia. J Neuroinflammation. 2017;14:33&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5303221</ArticleId><ArticleId IdType="pubmed">28187742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko M, Stellwagen D, Malenka RC, Stryker MP. Tumor necrosis factor-alpha mediates one component of competitive, experience-dependent plasticity in developing visual cortex. Neuron. 2008;58:673&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884387</ArticleId><ArticleId IdType="pubmed">18549780</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee AX, Hsu YT, Chen L. A metaplasticity view of the interaction between homeostatic and Hebbian plasticity. Philos Trans R Soc Lond B Biol Sci 2017; 372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5247587</ArticleId><ArticleId IdType="pubmed">28093549</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung YJ, Tweedie D, Scerba MT, Greig NH. Neuroinflammation as a factor of neurodegenerative disease: thalidomide analogs as treatments. Front Cell Dev Biol. 2019;7:313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6904283</ArticleId><ArticleId IdType="pubmed">31867326</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today. 1992;13:151&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">1322675</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewari M, Dixit VM. Recent advances in tumor necrosis factor and CD40 signaling. Curr Opin Genet Dev. 1996;6:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">8791485</ArticleId></ArticleIdList></Reference><Reference><Citation>Venters HD, Dantzer R, Kelley KW. A new concept in neurodegeneration: TNFalpha is a silencer of survival signals. Trends Neurosci. 2000;23:175&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">10717677</ArticleId></ArticleIdList></Reference><Reference><Citation>Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, Mora G, Camana C, Mazzini L, Bachetti T. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett. 2000;287:211&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">10863032</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott JL. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res. 2001;95:172&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">11687290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Fedynyshyn J, Ferrell S, Floyd RA, Gordon B, Grammas P, Hamdheydari L, Mhatre M, Mou S, Pye QN, et al. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis. 2003;14:74&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Floyd RA, Gordon B, Mou S, Pye QN, Stewart C, West M, Williamson K. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem. 2002;82:365&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">12124437</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyachandran A, Mertens B, McKissick EA, Mitchell CS. Type I vs. type II cytokine levels as a function of SOD1 G93A mouse amyotrophic lateral sclerosis disease progression. Front Cell Neurosci. 2015;9:462&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664727</ArticleId><ArticleId IdType="pubmed">26648846</ArticleId></ArticleIdList></Reference><Reference><Citation>Welser-Alves JV, Milner R. Microglia are the major source of TNF-alpha and TGF-beta1 in postnatal glial cultures; regulation by cytokines, lipopolysaccharide, and vitronectin. Neurochem Int. 2013;63:47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819935</ArticleId><ArticleId IdType="pubmed">23619393</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, Calingasan NY, Schafer P, Muller GW, Stewart C, et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2006;26:2467&#x2013;2473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793668</ArticleId><ArticleId IdType="pubmed">16510725</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkoski MJ, Droin NM, Green DR. Tumor necrosis factor alpha up-regulates non-lymphoid Fas-ligand following superantigen-induced peripheral lymphocyte activation. J Biol Chem. 2002;277:42380&#x2013;42385.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196549</ArticleId></ArticleIdList></Reference><Reference><Citation>Veglianese P, Lo Coco D, Bao Cutrona M, Magnoni R, Pennacchini D, Pozzi B, Gowing G, Julien JP, Tortarolo M, Bendotti C. Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Mol Cell Neurosci. 2006;31:218&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">16219474</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M, Veglianese P, Calvaresi N, Botturi A, Rossi C, Giorgini A, Migheli A, Bendotti C. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol Cell Neurosci. 2003;23:180&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">12812752</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Yamanaka K, Lobsiger C, Copeland N, Jenkins N, Kassiotis G, Kollias G, Cleveland D. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaarsma D, Teuling E, Haasdijk ED, De Zeeuw CI, Hoogenraad CC. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J Neurosci. 2008;28:2075&#x2013;2088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671838</ArticleId><ArticleId IdType="pubmed">18305242</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11:251&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>